Abstract | BACKGROUND: METHODS: A training set of 95 tumours from women with pure DCIS were immunostained for proteins involved in cell survival, hypoxia, growth factor and hormone signalling. A generalised linear regression with regularisation and variable selection was applied to a multiple covariate Cox survival analysis with recurrence-free survival 10-fold cross-validation and leave-one-out iterative approach were used to build and test the model that was validated using an independent cohort of 58 patients with pure DCIS. The clinical role of a COX-2-targeting agent was then tested in a proof-of-concept neoadjuvant randomised trial in ER-positive DCIS treated with exemestane 25 mg day(-1)± celecoxib 800 mg day(-1). RESULTS: The COX-2 expression was an independent prognostic factor for early relapse in the training (HR 37.47 (95% CI: 5.56-252.74) P=0.0001) and independent validation cohort (HR 3.9 (95% CI: 1.8-8.3) P=0.002). There was no significant interaction with other clinicopathological variables. A statistically significant reduction of Ki-67 expression after treatment with exemestane ± celecoxib was observed (P<0.02) with greater reduction in the combination arm (P<0.004). Concomitant reduction in COX-2 expression was statistically significant in the exemestane and celecoxib arm (P<0.03) only. CONCLUSIONS: In patients with DCIS, COX-2 may predict recurrence, aiding clinical decision making. A combination of an aromatase inhibitor and celecoxib has significant biological effect and may be integrated into treatment of COX2-positive DCIS at high risk of recurrence.
|
Authors | D Generali, F M Buffa, S Deb, M Cummings, L E Reid, M Taylor, D Andreis, G Allevi, G Ferrero, D Byrne, M Martinotti, A Bottini, A L Harris, S R Lakhani, S B Fox |
Journal | British journal of cancer
(Br J Cancer)
Vol. 111
Issue 1
Pg. 46-54
(Jul 08 2014)
ISSN: 1532-1827 [Electronic] England |
PMID | 24874483
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Androstadienes
- Aromatase Inhibitors
- Cyclooxygenase 2 Inhibitors
- Pyrazoles
- Sulfonamides
- Cyclooxygenase 2
- PTGS2 protein, human
- Celecoxib
- exemestane
|
Topics |
- Androstadienes
(administration & dosage, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Aromatase Inhibitors
(therapeutic use)
- Breast Neoplasms
(drug therapy, enzymology, pathology)
- Carcinoma, Intraductal, Noninfiltrating
(drug therapy, enzymology, pathology)
- Celecoxib
- Cohort Studies
- Cyclooxygenase 2
(biosynthesis, genetics)
- Cyclooxygenase 2 Inhibitors
(therapeutic use)
- Drug Resistance, Neoplasm
- Female
- Humans
- Middle Aged
- Neoadjuvant Therapy
- Neoplasm Recurrence, Local
(enzymology, pathology)
- Prognosis
- Pyrazoles
(administration & dosage)
- Sulfonamides
(administration & dosage)
- Survival Analysis
|